2020
DOI: 10.1016/j.jsbmb.2020.105602
|View full text |Cite
|
Sign up to set email alerts
|

Bifidobacterium pseudolongum reduces triglycerides by modulating gut microbiota in mice fed high-fat food

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

4
33
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 64 publications
(37 citation statements)
references
References 53 publications
4
33
0
Order By: Relevance
“…This result is consistent with the previous findings that Ama promotes the growth of probiotic bacteria in vitro, including Bifidobacterium [23]. Additionally, supplementation of Bifidobacterium pseudolongum significantly decreases the plasma TG levels in obese mice [24]. The current study found a strong negative correlation between the abundance of Bifidobacteriaceae and liver TG concentration.…”
Section: Discussionsupporting
confidence: 93%
“…This result is consistent with the previous findings that Ama promotes the growth of probiotic bacteria in vitro, including Bifidobacterium [23]. Additionally, supplementation of Bifidobacterium pseudolongum significantly decreases the plasma TG levels in obese mice [24]. The current study found a strong negative correlation between the abundance of Bifidobacteriaceae and liver TG concentration.…”
Section: Discussionsupporting
confidence: 93%
“…Adzuki bean is rich in polyphenols, dietary fiber, and protein ( Supplementary Table S1 ), which may contribute to the enrichment of Bifidobacterium . Importantly, Bifidobacterium supplementation has been reported to significantly reduce plasma TG level in obese mice [ 39 ]. In addition, Bifidobacterium can alleviate obesity, regulate glucose homeostasis, and produce short-chain fatty acids (SCFAs) [ 40 , 41 ].…”
Section: Discussionmentioning
confidence: 99%
“…Bifidobacterium pseudolongum enhances antitumor immunity ( Mager et al., 2020 ), exerts an anti-influenza effect ( Zhang et al., 2020 ), enhances the efficacy of anti-CTLA4 treatment ( Research, A. A for C. 2020 ), and treated obesity ( Bo et al., 2020 ) in an animal model, which inspired us to explore its mechanism from the perspectives of immunity and metabolism. Desulfovibrio piger was found to be significantly increased in patients with inflammatory bowel disease ( Loubinoux et al., 2002 ), but in recent population surveys it was used to predict preserved residual beta cell function in patients with type-1 diabetes ( de Groot et al., 2021 ), and was found to improve hyperglycemia and reduce insulin resistance ( Doumatey et al., 2020 ).…”
Section: Discussionmentioning
confidence: 99%